Targeted High-Dose Radiation Improves PFS, Progression in Oligometastatic Prostate Cancer

Jason Harris
Published: Tuesday, Oct 15, 2019
Ryan
Phillips, MD, PhD

Ryan Phillips, MD, PhD

In men with oligometastatic prostate cancer (OMPC), treatment with stereotactic ablative radiation (SABR) led to significant improvements in progression-free survival (PFS), especially in highrisk mutation-negative patients, and confirmed the value of tests for predicting benefit from SABR, according to findings from the phase II ORIOLE trial presented at the 61st Annual Meeting of the American Society for Radiation Oncology. SABR also stimulated levels of immune system activity that were thought impossible to achieve in prostate cancer.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x